Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xilio Therapeutics (XLO) Income from Continuing Operations (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Income from Continuing Operations for 2 consecutive years, with 11836000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 13.16% to 11836000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 41982000.0 through Dec 2025, up 30.7% year-over-year, with the annual reading at 41982000.0 for FY2025, 30.7% up from the prior year.
  • Income from Continuing Operations hit 11836000.0 in Q4 2025 for Xilio Therapeutics, down from 1929000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 1929000.0 in Q3 2025 to a low of 17487000.0 in Q1 2024.